Search

Your search keyword '"Reibaldi M"' showing total 438 results
Start Over Author "Reibaldi M"
438 results on '"Reibaldi M"'

1. A New and Easier Approach to Preserflo MicroShunt Implantation

Author

Fea AM, Ghilardi A, Bovone D, Reibaldi M, Rossi A, and Craven ER

Subjects
migs, open-angle glaucoma, preserflo, microshunt, glaucoma surgery, subconjunctival filtration surgery, Ophthalmology, RE1-994
Abstract

Antonio M Fea,1 Andrea Ghilardi,1 Davide Bovone,1 Michele Reibaldi,1 Alessandro Rossi,1 Earl R Craven2 1Dipartimento di Scienze Oftalmologiche-Universita’ di Torino, Torino, Italy; 2Glaucoma Center of Excellence, The Johns Hopkins Wilmer Eye Institute, Baltimore, Maryland, USACorrespondence: Antonio M Fea, Tel +39 3495601674, Email antoniomfea@gmail.comAbstract: PRESERFLO™ MicroShunt is a new minimally invasive glaucoma surgical (MIGS) device, implanted with an ab externo approach, which drains the aqueous humor to the subconjunctival space. It has been designed as a safer and less invasive approach for treating medically uncontrolled primary open-angle glaucoma (POAG) patients. The classic way of MicroShunt implantation involves different key steps, which includes creating a small scleral pocket with a 1mm blade; passing a 25-gauge (25G) needle through the scleral pocket into the anterior chamber (AC); and subsequently flushing the stent with a 23-gauge (23G) thin-wall cannula. However, sliding the needle into the scleral pocket can create false passages, thus making the device’s threading more difficult. The purpose of the current paper is to propose a simplified implantation approach. Our method proposes to make the scleral tunnel by using directly the 25G needle and, at the limbus, this 25G needle is used to slightly depress the sclera and enter into the AC. The MicroShunt is subsequently assembled on a 23G cannula mounted on a 1mL syringe. The syringe can then be used to flush the device. Outflow can thus be confirmed immediately by seeing drops of aqueous humor leaking from the external opening of the stent. This new approach may have different potential advantages, such as better control of the site of entry, avoids wrong passages, reduces or eliminates the risk of aqueous humor sideway flow, facilitates a parallel path to the iris plane, and it is faster.Keywords: MIGS, open-angle glaucoma, Preserflo, MicroShunt, glaucoma surgery, subconjunctival filtration surgery

Published
2022

2. Widening use of dexamethasone implant for the treatment of macular edema

Author

Bonfiglio V, Reibaldi M, Fallico M, Russo A, Pizzo A, Fichera S, Rapisarda C, Macchi I, Avitabile T, and Longo A

Subjects
Macular edema, dexamethasone, intravitreal, implant, corticosteroids, Therapeutics. Pharmacology, RM1-950
Abstract

Vincenza Bonfiglio, Michele Reibaldi, Matteo Fallico, Andrea Russo, Alessandra Pizzo, Stefano Fichera, Carlo Rapisarda, Iacopo Macchi, Teresio Avitabile, Antonio Longo Department of Ophthalmology, University of Catania, Catania, Italy Abstract: Sustained-release intravitreal 0.7 mg dexamethasone (DEX) implant is approved in Europe for the treatment of macular edema related to diabetic retinopathy, branch retinal vein occlusion, central retinal vein occlusion, and non-infectious uveitis. The implant is formulated in a biodegradable copolymer to release the active ingredient within the vitreous chamber for up to 6 months after an intravitreal injection, allowing a prolonged interval of efficacy between injections with a good safety profile. Various other ocular pathologies with inflammatory etiopathogeneses associated with macular edema have been treated by DEX implant, including neovascular age-related macular degeneration, Irvine–Gass syndrome, vasoproliferative retinal tumors, retinal telangiectasia, Coats’ disease, radiation maculopathy, retinitis pigmentosa, and macular edema secondary to scleral buckling and pars plana vitrectomy. We undertook a review to provide a comprehensive collection of all of the diseases that benefit from the use of the sustained-release DEX implant, alone or in combination with concomitant therapies. A MEDLINE search revealed lack of randomized controlled trials related to these indications. Therefore we included and analyzed all available studies (retrospective and prospective, comparative and non-comparative, randomized and nonrandomized, single center and multicenter, and case report). There are reports in the literature of the use of DEX implant across a range of macular edema-related pathologies, with their clinical experience supporting the use of DEX implant on a case-by-case basis with the aim of improving patient outcomes in many macular pathologies. As many of the reported macular pathologies are difficult to treat, a new treatment option that has a beneficial influence on the clinical course of the disease may be useful in clinical practice. Keywords: macular edema, dexamethasone, intravitreal, implant, corticosteroids

Published
2017

4. Validation of Esaso Classification of Diabetic Maculopathy

Author

Panozzo, G., Franzolin, E., Giannarelli, Diana, Dalla Mura, G., Longo, Anita Rosa, Cicinelli, M. V., Angelini, E., Airaghi, P., Avitabile, T., Bandello, F., Beccastrini, A., Benedetti, G., Bertuzzi, Paolo Francesco, Bonfiglio, V. M. E., Boscia, F., Carnevali, A., Carosielli, M., Cereda, M. G., Contardi, C., Coppola, M., Costagliola, C., Cristofolini, R., Cucciniello, P., D'Aloisio, R., De Bernardo, M., De Filippis, Alessandro, Dell'Omo, Roberto, Di Paola, I., Dell'Acqua, Massimiliano, Franco, Alessio, Grassi, M. O., Gregori, G., Gusson, E., Lattanzio, R., Lanzetta, P., Longo, A., Marchini, G., Marolo, P., Mastropasqua, R., Bertoldo, G. M., Monteleone, Giorgio, Ortisi, E., Parisi, Giuseppe, Parrulli, S., Pucci, P., Pastore, M. R., Reibaldi, M., Rizzo, Stanislao, Romano, Federica, Rosa, N., Sarao, V., Scarpa, G., Scorcia, V., Scupola, Andrea, Staurenghi, G., Sunseri Trapani, V., Tognetto, D., Trabucchi, G., Vaccaro, S., Vadala, M., Veritti, D., Vinciguerra, A. L., Zanzottera, E. C., Giannarelli D., Longo R., Bertuzzi F., De Filippis A., Dell'Omo R., Dell'Acqua M., Franco A., Monteleone G., Parisi G., Rizzo S. (ORCID:0000-0001-6302-063X), Romano F., Scupola A., Panozzo, G., Franzolin, E., Giannarelli, Diana, Dalla Mura, G., Longo, Anita Rosa, Cicinelli, M. V., Angelini, E., Airaghi, P., Avitabile, T., Bandello, F., Beccastrini, A., Benedetti, G., Bertuzzi, Paolo Francesco, Bonfiglio, V. M. E., Boscia, F., Carnevali, A., Carosielli, M., Cereda, M. G., Contardi, C., Coppola, M., Costagliola, C., Cristofolini, R., Cucciniello, P., D'Aloisio, R., De Bernardo, M., De Filippis, Alessandro, Dell'Omo, Roberto, Di Paola, I., Dell'Acqua, Massimiliano, Franco, Alessio, Grassi, M. O., Gregori, G., Gusson, E., Lattanzio, R., Lanzetta, P., Longo, A., Marchini, G., Marolo, P., Mastropasqua, R., Bertoldo, G. M., Monteleone, Giorgio, Ortisi, E., Parisi, Giuseppe, Parrulli, S., Pucci, P., Pastore, M. R., Reibaldi, M., Rizzo, Stanislao, Romano, Federica, Rosa, N., Sarao, V., Scarpa, G., Scorcia, V., Scupola, Andrea, Staurenghi, G., Sunseri Trapani, V., Tognetto, D., Trabucchi, G., Vaccaro, S., Vadala, M., Veritti, D., Vinciguerra, A. L., Zanzottera, E. C., Giannarelli D., Longo R., Bertuzzi F., De Filippis A., Dell'Omo R., Dell'Acqua M., Franco A., Monteleone G., Parisi G., Rizzo S. (ORCID:0000-0001-6302-063X), Romano F., and Scupola A.

Abstract

Purpose: To test reliability and reproducibility of ESASO morphologic OCT-based classification of diabetic maculopathy (DM). Methods: This is a multi-center cross-sectional study including a coordination center (CC) and 18 participating centers (PCs). After instruction on the correct use of ESASO Classification, the validation process was carried out in two consecutive stages. In the first retrospective phase, we evaluated the concordance between PCs and CC in the staging of OCT images collected during PCs’ daily activity (608 images). In a second prospective phase, we analyzed the inter-observer agreement of staging assigned by each PCs to OCT images selected by the CC (22 images). Results: The overall concordance achieved in the retrospective phase was 89.8% (Kappa = 0.83 (95% CI: 0.78–0.87); p<0.0001). In 99.5% of cases, concordance did not differ by more than one stage. In the prospective phase, PCs reached an inter-operator agreement of 93.0% (Krippendorff's Alpha = 0.953, 95% CI: 0.929–0.977, p<0.0001). Any discrepancy among the 22 images was within one stage. Conclusion: The results achieved in this study confirm that ESASO OCT-based Classification can be considered as an easy and reproducible method to stage DM during clinical practice. A diffused use of a common and validated method to describe the progression of retinal damage in DM may offer several clinical and scientific advantages.

Published
2023

5. Effect of COVID-19-related lockdown on ophthalmic practice in Italy: A report from 39 institutional centers

Author

Dell'Omo, Roberto, Filippelli, M., Virgili, Gianni, Bandello, F., Querques, G., Lanzetta, P., Avitabile, T., Viola, F., Reibaldi, M., Semeraro, F., Quaranta, L., Rizzo, Stanislao, Midena, E., Campagna, G., Costagliola, C., Marolo, P., Traverso, C. E., Iester, M., Cutolo, C. A., Azzolini, C., Donati, S., Premi, E., Nucci, P., Vujosevic, S., Staurenghi, G., Bottoni, F., Romano, Federica, Grosso, D., Borrelli, E., Sacconi, R., Milella, P., Ganci, S., Romano, M. R., Ricciardelli, G., Allegrini, D., Casaluci, M., Romano, D., Marchini, G., Chemello, F., Amantea, Carlotta, Frisina, R., Pilotto, E., Parrozzani, R., Veritti, D., Sarao, V., Daniele, T., Busin, M., Parmeggiani, F., De Nadai, K., Furiosi, L., Mastropasqua, R., Battaglia, B., Gironi, Marco, Gandolfi, S., Luciani, E., Mora, P., Schiavi, C., Bertaccini, Paolo Antonio, Finzi, A., Roda, M., Cagini, C., Lupidi, M., Giansanti, F., Bacherini, Daniela, Tosi, G., De Benedetto, E., Nardi, M., Figus, M., Posarelli, C., Mariotti, Cesare, Pirani, V., Nicolai, Massimo, Bonini, S., Coassin, M., Di Zazzo, A., Savastano, Maria Cristina, Savastano, Alfonso, Gambini, Gloria, Vico, U. D., Spadea, L., Iannaccone, A., Nucci, C., Ricci, F., Aiello, F., Afflitto, G. G., Mastropasqua, L., D'Onofio, G., Evangelista, F., Brescia, L., Napolitano, P., Polisena, P., Gianfrancesco, N., Trivisonno, D., Petti, F., Simonelli, F., Rossi, S., Tartaglione, A., Rosa, N., Bernardo, M. D., Iaculli, C., Valeria Bux, A., Maggiore, Giuseppe, Boscia, F., Sborgia, G., Grassi, M. O., Scorcia, V., Giannaccare, G., Parisi, Giuseppe, Cillino, S., Alaimo, F., Aragona, P., Meduri, A., Pinna, A., Sollazzo, A., Peiretti, E., Siotto, E., dell'Omo R., Virgili G., Rizzo S. (ORCID:0000-0001-6302-063X), Romano F., Amantea C., Gironi M., Bertaccini P., Bacherini D., Mariotti C., Nicolai M., Savastano M. (ORCID:0000-0003-1397-4333), Savastano A., Gambini G., Maggiore G., Parisi G., Dell'Omo, Roberto, Filippelli, M., Virgili, Gianni, Bandello, F., Querques, G., Lanzetta, P., Avitabile, T., Viola, F., Reibaldi, M., Semeraro, F., Quaranta, L., Rizzo, Stanislao, Midena, E., Campagna, G., Costagliola, C., Marolo, P., Traverso, C. E., Iester, M., Cutolo, C. A., Azzolini, C., Donati, S., Premi, E., Nucci, P., Vujosevic, S., Staurenghi, G., Bottoni, F., Romano, Federica, Grosso, D., Borrelli, E., Sacconi, R., Milella, P., Ganci, S., Romano, M. R., Ricciardelli, G., Allegrini, D., Casaluci, M., Romano, D., Marchini, G., Chemello, F., Amantea, Carlotta, Frisina, R., Pilotto, E., Parrozzani, R., Veritti, D., Sarao, V., Daniele, T., Busin, M., Parmeggiani, F., De Nadai, K., Furiosi, L., Mastropasqua, R., Battaglia, B., Gironi, Marco, Gandolfi, S., Luciani, E., Mora, P., Schiavi, C., Bertaccini, Paolo Antonio, Finzi, A., Roda, M., Cagini, C., Lupidi, M., Giansanti, F., Bacherini, Daniela, Tosi, G., De Benedetto, E., Nardi, M., Figus, M., Posarelli, C., Mariotti, Cesare, Pirani, V., Nicolai, Massimo, Bonini, S., Coassin, M., Di Zazzo, A., Savastano, Maria Cristina, Savastano, Alfonso, Gambini, Gloria, Vico, U. D., Spadea, L., Iannaccone, A., Nucci, C., Ricci, F., Aiello, F., Afflitto, G. G., Mastropasqua, L., D'Onofio, G., Evangelista, F., Brescia, L., Napolitano, P., Polisena, P., Gianfrancesco, N., Trivisonno, D., Petti, F., Simonelli, F., Rossi, S., Tartaglione, A., Rosa, N., Bernardo, M. D., Iaculli, C., Valeria Bux, A., Maggiore, Giuseppe, Boscia, F., Sborgia, G., Grassi, M. O., Scorcia, V., Giannaccare, G., Parisi, Giuseppe, Cillino, S., Alaimo, F., Aragona, P., Meduri, A., Pinna, A., Sollazzo, A., Peiretti, E., Siotto, E., dell'Omo R., Virgili G., Rizzo S. (ORCID:0000-0001-6302-063X), Romano F., Amantea C., Gironi M., Bertaccini P., Bacherini D., Mariotti C., Nicolai M., Savastano M. (ORCID:0000-0003-1397-4333), Savastano A., Gambini G., Maggiore G., and Parisi G.

Abstract

Background/objectives: To compare the number of eye surgical procedures performed in Italy in the 2 months following the beginning of lockdown (study period) because of COVID-19 epidemic with those performed in the two earlier months of the same year (intra-year control) and in the period of 2019 corresponding to the lockdown (inter-year control). Methods: Retrospective analysis of surgical procedures carried out at 39 Academic hospitals. A distinction was made between elective and urgent procedures. Intravitreal injections were also considered. Percentages for all surgical procedures and incidence rate ratios (IRR) for rhegmatogenous retinal detachment (RRD) events were calculated. A p value <0.05 was considered significant. Results: A total of 20,886 versus 55,259 and 56,640 patients underwent surgery during the lockdown versus intra-and inter-year control periods, respectively. During the lockdown, only 70% of patients for whom an operation/intravitreal injection was recommended, finally underwent surgery; the remaining patients did not attend because afraid of getting infected at the hospital (23%), taking public transportation (6.5%), or unavailable swabs (0.5%). Elective surgeries were reduced by 96.2% and 96.4%, urgent surgeries by 49.7% and 50.2%, and intravitreal injections by 48.5% and 48.6% in the lockdown period in comparison to intra-year and inter-year control periods, respectively. IRRs for RRDs during lockdown dropped significantly in comparison with intra- and inter-year control periods (CI: 0.65–0.80 and 0.61–0.75, respectively, p < 0.001 for both). Conclusion: This study provides a quantitative analysis of the reduction of eye surgical procedures performed in Italy because of the COVID-19 epidemic.

Published
2022

6. Correction: Circulating insulin-like growth factor-1: A new clue in the pathogenesis of age-related macular degeneration [Aging (Albany NY), 10 (2018) (4241-4247)] DOI:10.18632/aging.101727

Author

Castellino, N., Longo, A., Avitabile, T., Russo, A., Fallico, M., Bonfiglio, V., Toro, M. D., Rejdak, R., Murabito, P., Furino, C., Reibaldi, M., Castellino N., Longo A., Avitabile T., Russo A., Fallico M., Bonfiglio V., Toro M.D., Rejdak R., Murabito P., Furino C., Reibaldi M., Castellino, N., Longo, A., Avitabile, T., Russo, A., Fallico, M., Bonfiglio, V., Toro, M. D., Rejdak, R., Murabito, P., Furino, C., and Reibaldi, M.

Subjects
correction
Abstract

circulating insulin like

Published
2018

9. Prevalence of diabetes and diabetic macular edema in patients undergoing senile cataract surgery in Italy: The DIabetes and CATaract study

Author

Panozzo, G., Staurenghi, G., Dalla Mura, G., Giannarelli, Diana, Alessio, G., Alongi, S., Appolloni, R., Baldascino, Antonio, Boscia, F., Caporossi, Aldo, Cereda, M., D'Ugo, E., Fallico, M., Avitabile, T., Galan, A., La Spina, C., Lo Giudice, G., Mastropasqua, L., Palmisano, C., Panico, C., Parravano, M. C., Penna, R., Pintore, P., Vaiano, A., Reibaldi, M., Rizzo, Stanislao, Rossi, Tommaso, Varano, M., Virgili, Gianni, Giannarelli D., Baldascino A., Caporossi A. (ORCID:0000-0002-8680-3773), Rizzo S. (ORCID:0000-0001-6302-063X), Rossi T., Virgili G., Panozzo, G., Staurenghi, G., Dalla Mura, G., Giannarelli, Diana, Alessio, G., Alongi, S., Appolloni, R., Baldascino, Antonio, Boscia, F., Caporossi, Aldo, Cereda, M., D'Ugo, E., Fallico, M., Avitabile, T., Galan, A., La Spina, C., Lo Giudice, G., Mastropasqua, L., Palmisano, C., Panico, C., Parravano, M. C., Penna, R., Pintore, P., Vaiano, A., Reibaldi, M., Rizzo, Stanislao, Rossi, Tommaso, Varano, M., Virgili, Gianni, Giannarelli D., Baldascino A., Caporossi A. (ORCID:0000-0002-8680-3773), Rizzo S. (ORCID:0000-0001-6302-063X), Rossi T., and Virgili G.

Abstract

Background: The purpose of this study is to determine the prevalence of diabetes and diabetic macular edema in patients undergoing senile cataract surgery in Italy. Methods: It is a prospective, multicenter, cross-sectional study. Thirteen ophthalmic units equally distributed across the Italian territory have been involved in the study. For a period of 3 months, all subjects undergoing phacoemulsification received an Optical Coherence Tompgraphy (OCT) scan and were screened for the anamnestic presence of diabetes. In addition, five selected units collected blood samples from all their patients to measure glycated hemoglobin (HbA1c) levels and detect the presence of occult diabetes (HbA1c > 6.5%). In diabetic patients, levels of retinopathy were measured and diabetic macular edema was considered significant (clinically significant macular edema) when foveal thickness was above 30% of normal levels. Results: A total number of 3657 subjects have been screened. Among them, 20.4% were diabetics. Prevalence of diabetes was significantly higher in males (24.7%) than in females (17%). Levels of HbA1c were tested in a representative sample of 1216 consecutive subjects, and occult diabetes was diagnosed in 4.8% of cases. No significant differences were observed between age groups or different geographic areas. Among diabetic patients, diabetic macular edema of any kind was present in 27.5% (clinically significant macular edema (6.6%)). No significant differences were seen in the prevalence of diabetic macular edema between males and females or between age groups. Among the 745 diabetic patients, no signs of retinopathy were seen in 537 subjects (76.3%), while 101 patients (14.3%) had nonproliferative retinopathy, 13 (1.7%) had nontreated proliferative diabetic retinopathy, and 53 (7.5%) had laser-treated retinopathy. In the entire sample of 3657 subjects, a normal macula was present in 90.9% of cases, diabetic macular edema of any kind in 5.4%, and other maculopathies in 3

Published
2020

12. The Effectiveness of 0.6% Povidone Iodine Eye Drops in Reducing the Conjunctival Bacterial Load and Needle Contamination in Patients Undergoing Anti-VEGF Intravitreal Injection: A Prospective, Randomized Study

Author

Reibaldi, M, Avitabile, T, Bandello, F, Longo, A, Bonfiglio, V, Russo, A, Castellino, N, Rejdak, R, Nowomiejska, K, Toro, M, Furino, C, Cillino, S, Fiore, T, Cagini, C, Grassi, P, Musumeci, R, Cocuzza, C, Martinelli, M, Fallico, M, Cocuzza, CE, Reibaldi, M, Avitabile, T, Bandello, F, Longo, A, Bonfiglio, V, Russo, A, Castellino, N, Rejdak, R, Nowomiejska, K, Toro, M, Furino, C, Cillino, S, Fiore, T, Cagini, C, Grassi, P, Musumeci, R, Cocuzza, C, Martinelli, M, Fallico, M, and Cocuzza, CE

Abstract

The study purpose was to assess the efficacy of a preservative-free 0.6% povidone iodine eye drops as perioperative prophylactic treatment for reducing conjunctival bacterial load and the rate of needle contamination in patients undergoing intravitreal anti-vascular endothelial growth factor injection. Enrolled patients were randomized to either the study group (0.6% povidone iodine, three day-prophylactic treatment before the injection) or to the control group (placebo, three day-prophylactic treatment). Conjunctival swabs were obtained before and after the prophylactic treatment in both groups. Intravitreal injections were performed in a sterile fashion. The injection needle and a control needle were collected for microbiological culture. Data from 254 and 253 eyes in the study group and control group, respectively, were analyzed. Bacterial growth from conjunctival swab cultures was significantly lower after 0.6% povidone iodine prophylaxis compared to baseline and to placebo prophylaxis (p < 0.001), showing an 82% eradication rate in the study group. No injection needle showed bacterial contamination in the study group, whereas six needles were culture-positive in the control group (p = 0.015). No serious ocular and non-ocular adverse events were recorded. The 0.6% povidone iodine solution proved an effective treatment in reducing conjunctival bacterial load and risk of needle contamination.

Published
2019

14. miRNAs in the vitreous humor of patients affected by idiopathic epiretinal membrane and macular hole

Author

Russo A, Ragusa M, Barbagallo C, Longo A, Avitabile T, Uva MG, Bonfiglio V, Toro M, Caltabiano R, Mariotti C, Boscia F, Romano MR, Di Pietro C, Barbagallo D, Purrello M, Reibaldi M, Russo, Andrea, Ragusa, Marco, Barbagallo, Cristina, Longo, Antonio, Avitabile, Teresio, Uva, Maurizio G, Bonfiglio, Vincenza, Toro, Mario D, Caltabiano, Rosario, Mariotti, Cesare, Boscia, Francesco, Romano, Mario R, Di Pietro, Cinzia, Barbagallo, Davide, Purrello, Michele, Reibaldi, Michele, Russo, A, Ragusa, M, Barbagallo, C, Longo, A, Avitabile, T, Uva, Mg, Bonfiglio, V, Toro, M, Caltabiano, R, Mariotti, C, Boscia, F, Romano, Mr, Di Pietro, C, Barbagallo, D, Purrello, M, and Reibaldi, M

Subjects
Male, Multidisciplinary, lcsh:R, lcsh:Medicine, Correction, Down-Regulation, Epiretinal Membrane, Middle Aged, Retinal Perforations, Vitreous Body, MicroRNAs, Vitrectomy, Humans, lcsh:Q, Female, Prospective Studies, lcsh:Science, Transcriptome, miRNA, macular hole
Abstract

The aim of the present study was to assess the expression of miRNAs in the Vitreous Humor (VH) of patients with Macular Hole (MH) and Epiretinal Membrane (ERM) compared to a control group.In this prospective, comparative study, 2-ml of VH was extracted from the core of the vitreous chamber in consecutive patients who underwent standard vitrectomy for ERM and MH. RNA was extracted and TaqMan® Low Density Arrays (TLDAs) were used to profile the transcriptome of 754 miRNAs. Results were validated by single TaqMan® assays. Finally, we created a biological network of differentially expressed miRNA targets and their nearest neighbors.Overall 10 eyes with MH, 16 eyes with idiopathic ERM and 6 controls were enrolled in the study. Profiling data identified 5 miRNAs differentially expressed in patients affected by MH and ERM with respect to controls. Four were downregulated (miR-19b, miR-24, miR-155, miR-451) and 1 was downregulated (miR-29a); TaqMan® assays of the VH of patients affected by MH and ERM, with respect to controls, showed that the most differentially expressed were miR-19b (FC -9.13, p:0.00004), mir-24 (FC -7.52, p:0.004) and miR-142-3p (FC -5.32, p:0.011). Our network data showed that deregulation of differentially expressed miRNAs induces an alteration of several pathways associated with genes involved in both MH and ERM.The present study suggests that disregulation of miR-19b, miR-24 and miR-142-3p, might be related to the alterations that characterize patients affected by MH and ERM.

Published
2017

35. Documento di consenso: Gestione dei pazienti con diagnosi di occlusione venosa retinica

Author

Bandello F, Varano M, Battaglia Parodi M, Boscia F, D'Angelo A, Eandi CM, Giovannini A, Lanzetta P, Midena E, Parravano MC, Ratiglia R, Reibaldi M, Sodi A, Staurenghi G, Bandello F, Bandello, F, Varano, M, Battaglia Parodi, M, Boscia, F, D'Angelo, A, Eandi, Cm, Giovannini, A, Lanzetta, P, Midena, E, Parravano, Mc, Ratiglia, R, Reibaldi, M, Sodi, A, and Staurenghi, G

Published
2010

37. Documento di Consenso: Prevenzione e Terapia Medica della Degenerazione Maculare Legata all'Età

Author

Bandello, F, Battaglia Parodi, M, Boscia, F, Eandi, Chiara Maria, Giovannini, A, Introini, U, Menchini, U, Pazzaglia, A, Piermarocchi, S, Reibaldi, M, Varano, M., Bandello F., Battaglia Parodi M., Boscia F., Eandi C.M., Giovannini A., Introini U., Manchini U., Pazzaglia A., Piermarocchi S., Reibaldi M., and Varano M.

Subjects
DEGENERAZIONE MACULARE CORRELATA ALL'ETÀ
Abstract

La degenerazione maculare legata all'età (detta anche degenerazione maculare senile ovvero AMD) è attualmente la prima causa di cecità o di ipovisione nei Paesi occidentali. In Italia si calcola che siano affetti da AMD oltre 765.000 individui (altre stime indicano un milione di persone); ogni anno si verificano tra i 63mila e i 91mila casi. Il volume tratta un documento di consensus elaborato tra i più autorevoli esponenti dell'oftalmologia nazionale

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results